Cytokinetics (NASDAQ:CYTK) CEO Sells 7,500 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 7,500 shares of Cytokinetics stock in a transaction on Monday, October 12th. The stock was sold at an average price of $62.88, for a total value of $471,600.00. Following the sale, the chief executive officer directly owned 278,544 shares of the company’s stock, valued at $17,514,846.72. This represents a 2.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Stock Down 1.9%

Shares of Cytokinetics stock traded down $1.17 during trading on Tuesday, reaching $61.62. The company’s stock had a trading volume of 1,935,741 shares, compared to its average volume of 2,140,254. The business’s 50-day moving average price is $71.47 and its 200-day moving average price is $73.28. The firm has a market cap of $7.67 billion, a PE ratio of -8.53 and a beta of 0.41. Cytokinetics, Incorporated has a 52 week low of $54.30 and a 52 week high of $88.31.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.13. The business had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. During the same quarter last year, the company posted ($1.12) earnings per share. The company’s revenue was down 57.1% on a year-over-year basis. Equities analysts predict that Cytokinetics, Incorporated will post -5.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

CYTK has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Cytokinetics from $97.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. HC Wainwright reissued a “buy” rating and set a $140.00 price target on shares of Cytokinetics in a research report on Monday, August 31st. Needham & Company LLC increased their price target on Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Royal Bank Of Canada raised their price objective on Cytokinetics from $112.00 to $113.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Finally, Mizuho raised their price objective on Cytokinetics from $100.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 24th. Eighteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $106.06.

Institutional Investors Weigh In On Cytokinetics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Mirador Capital Partners LP lifted its holdings in shares of Cytokinetics by 3.2% in the third quarter. Mirador Capital Partners LP now owns 208,896 shares of the biopharmaceutical company’s stock worth $13,768,000 after acquiring an additional 6,526 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Cytokinetics by 8.6% in the 3rd quarter. GAMMA Investing LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 213 shares in the last quarter. Cim Investment Management Inc. grew its holdings in shares of Cytokinetics by 20.9% during the 2nd quarter. Cim Investment Management Inc. now owns 5,657 shares of the biopharmaceutical company’s stock valued at $482,000 after purchasing an additional 979 shares during the last quarter. Tidal Investments LLC grew its holdings in shares of Cytokinetics by 24.7% during the 2nd quarter. Tidal Investments LLC now owns 24,921 shares of the biopharmaceutical company’s stock valued at $2,123,000 after purchasing an additional 4,938 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new position in Cytokinetics during the 2nd quarter worth approximately $774,000.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Additional ACACIA-HCM analyses indicated that aficamten improved exercise performance across multiple measures in patients with non-obstructive HCM. The presentation also addressed treatment response, dose titration and safety, strengthening the case for aficamten’s potential clinical and commercial value. Cytokinetics Announces Additional Data from ACACIA-HCM
• Positive Sentiment: Reports highlighted exercise-capacity improvements and responder data for aficamten, suggesting that meaningful benefits may extend beyond a narrow subgroup of patients. This is positive for expectations surrounding future regulatory filings and market adoption. Cytokinetics Highlights Aficamten Responder Data
• Positive Sentiment: Coverage characterized the Phase 3 results as gains in non-obstructive HCM and suggested that aficamten’s multi-domain benefits could materially improve the investment thesis for Cytokinetics. Cytokinetics Phase 3 Aficamten Gains
• Neutral Sentiment: Analyst and media coverage remains mixed: some commentary points to substantial upside based on aficamten and Cytokinetics’ pipeline, while other reports say the stock is difficult to pin down following the strong heart-drug updates. Cytokinetics Stock Analysis
• Negative Sentiment: Despite the favorable data, aficamten’s ultimate regulatory outcome, launch timing and commercial uptake remain uncertain. Comparisons with other biotech companies and a recent upgrade to a “Hold” rating provide limited direct catalysts and may be contributing to cautious trading. Wall Street Zen Upgrades Cytokinetics to Hold

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.

Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle.